Company: BIVIW
Filing Date: 2025-08-08
Form Type: 424B5
Source: 0001520138-25-000247
Chunk: 57

Company: BIOVIE INC.
Filing Date: 2025-08-08
Form: 424B5
Chunk 57
---
 or more licenses from third parties,
which may be impossible or require substantial time and monetary expenditure. Claims that we have misappropriated the confidential information
or trade secrets of third parties could have a similar negative impact on our business. Any of the foregoing events would harm our business,
financial condition, results of operations and prospects.

<div align='center'>26</div>

We may be subject to claims by third parties asserting that we or our employees have infringed, misappropriated or otherwise violated their intellectual property rights, or claiming ownership of what we regard as our own intellectual property.

Many of our employees were previously employed
at other biotechnology or pharmaceutical companies. Although we try to ensure that our employees, consultants and advisors do not use
the proprietary information or know-how of others in their work for us, we may be subject to claims that we or these individuals have
used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s former
employer. We may also be subject to claims that patents and applications we have filed to protect inventions made on our behalf by our
employees, consultants and advisors, even those related to one or more of our drug candidates, are rightfully owned by their former or
concurrent employer. Litigation may be necessary to defend against these claims

If we fail in prosecuting or defending any such
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful
in prosecuting or defending against such claims, litigation could result in substantial costs, delay development of our drug candidates
and be a distraction to management. Any of the foregoing events would harm our business, financial condition, results of operations and
prospects.

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

We or our licensors may be subject to claims that
former employees, collaborators or other third parties have an interest (including co-ownership or ownership) in our owned or in-licensed
patents, trade secrets, or other intellectual property as an inventor or co-inventor. For example, we or our licensors or collaborators
may have inventorship disputes arising from conflicting obligations of employees, consultants or others who are involved in developing
our drug candidates. While it is our policy to require our employees and contractors who may be involved in the development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with
each party who in fact develops intellectual property that